GDF15 can be used as a potential predictive biomarker for TPF induction chemotherapy in patients with locally advanced oral squamous cell carcinoma

Abstract

Abstract: PURPOSE: To figure out the prognostic value of GDF15 expression in patients with locally advanced oral squamous cell carcinoma (OSCC), and to explore the clinical usefulness of GDF15 as a potential predictive biomarker for TPF (docetaxel, cisplatin and 5-fluorouracil) induction chemotherapy. METHODS: Two hundred and fifty-six patients with locally advanced OSCC from a prospective, randomized trial were enrolled into this study. Immunohistochemical staining against GDF15 was used in the biopsy specimens from these patients. Prognostic analysis was performed in these patients, especially on the relationship between GDF15 expression and TPF induction chemotherapy. SPSS18.0 software package was used for statistical analysis. RESULTS: Among the 230 patients with biopsy specimens, lower GDF15 expression was detected in 68 patients and higher GDF15 expression in 162 patients. The patients with lower GDF15 expression had a better survival than those with higher GDF15 expression, including overall survival(P=0.046), disease-free survival(P=0.0496), locoregional recurrence-free survival(P=0.065) and distant metastasis-free survival(P=0.017). Furthermore, the cN- patients with higher GDF15 expression could benefit from TPF induction chemotherapy, including overall survival(P=0.018), disease-free survival (P=0.010), locoregional recurrence-free survival (P=0.042) and distant metastasis-free survival(P=0.006). CONCLUSIONS: GDF15 expression could be used as a prognostic biomarker for patients with locally advanced OSCC. cN- patients with higher GDF15 expression could benefit from TPF induction chemotherapy.

Key words: Growth differentiation factor 15, GDF 15, Oral squamous cell carcinoma, Induction chemotherapy, Prognostic biomarker, Predictive biomarker

CLC Number:

R739.8

TANG Xiao, SUN Wen-wen, ZHU Dong-wang, MA Jie, MA Hai-long, LIU Ying, TAN Yi-ran, TU Yao-yao, WANG Li-zhen, LI Jiang, ZHONG Lai-ping, ZHANG Chen-ping, ZHNAG Zhi-yuan. GDF15 can be used as a potential predictive biomarker for TPF induction chemotherapy in patients with locally advanced oral squamous cell carcinoma[J]. China Journal of Oral and Maxillofacial Surgery, 2016, 14(2): 117-122.

References

[1] Leemans CR, Braakhuis BJ, Brakenhoff RH. The molecular biology of head and neck cancer[J]. Nat Rev Cancer, 2011, 11(1): 9-22.
[2] Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012 [J]. CA Cancer J Clin, 2015, 65(2): 87-108.
[3] Pfister DG, Spencer S, Brizel DM, et al. Head and neck cancers, Version 2.2014. Clinical practice guidelines in oncology [J]. J Natl Compr Canc Netw, 2014, 12(10): 1454-1487.
[4] Benasso M. Induction chemotherapy for squamous cell head and neck cancer: a neverending story?[J]. Oral Oncol, 2013, 49(8): 747-752.
[5] Zhong LP, Zhang CP, Ren GX, et al. Randomized phase Ⅲ trial of induction chemotherapy with docetaxel, cisplatin, and fluorouracil followed by surgery versus up-front surgery in locally advanced resectable oral squamous cell carcinoma [J]. J Clin Oncol, 2013, 31(6): 744-751.
[6] Unsicker K, Spittau B, Krieglstein K. The multiple facets of the TGF-beta family cytokine growth/differentiation factor-15/macrophage inhibitory cytokine-1 [J]. Cytokine Growth Factor Rev, 2013, 24(4): 373-384.
[7] Mimeault M, Batra SK. Divergent molecular mechanisms underlying the pleiotropic functions of macrophage inhibitory cytokine-1 in cancer [J]. J Cell Physiol, 2010, 224(3): 626-635.
[8] Khaled YS, Elkord E, Ammori BJ. Macrophage inhibitory cytokine-1: a review of its pleiotropic actions in cancer [J]. Cancer Biomark, 2012, 11(5): 183-190.
[9] Brown DA, Lindmark F, Stattin P, et al. Macrophage inhibitory cytokine 1: a new prognostic marker in prostate cancer [J]. Clin Cancer Res, 2009, 15(21): 6658-6664.
[10] Wallin U, Glimelius B, Jirström K, et al. Growth differentiation factor 15: a prognostic marker for recurrence in colorectal cancer [J]. Br J Cancer, 2011, 104(10): 1619-1627.
[11] Staff AC, Bock AJ, Becker C, et al. Growth differentiation factor-15 as a prognostic biomarker in ovarian cancer [J]. Gynecol Oncol, 2010, 118(3): 237-243.
[12] Staff AC, Trovik J, Eriksson AG, et al. Elevated plasma growth differentiation factor-15 correlates with lymph node metastases and poor survival in endometrial cancer [J]. Clin Cancer Res, 2011, 17(14): 4825-4833.
[13] Bock AJ, Stavnes HT, Kempf T, et al. Expression and clinical role of growth differentiation factor-15 in ovarian carcinoma effusions [J]. Int J Gynecol Cancer, 2010, 20(9): 1448-1455.
[14] Zhao L, Lee BY, Brown DA, et al. Identification of candidate biomarkers of therapeutic response to docetaxel by proteomic profiling [J]. Cancer Res, 2009, 69(19): 7696-7703.
[15] Zhang L, Yang X, Pan HY, et al. Expression of growth differentiation factor 15 is positively correlated with histopathological malignant grade and in vitro cell proliferation in oral squamous cell carcinoma [J]. Oral Oncol,2009,45(7): 627-632.